Coya Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.41) Per Share, HC Wainwright Forecasts (NASDAQ:COYA)

Coya Therapeutics, Inc. (NASDAQ:COYA) – Research analysts at HC Wainwright issued their Q3 2024 earnings estimates for shares of Coya Therapeutics in a research report issued on Monday, September 16th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.41) per share for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q4 2024 earnings at ($0.43) EPS, FY2024 earnings at ($1.38) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($1.48) EPS.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.19) earnings per share for the quarter. The company had revenue of $3.43 million during the quarter.

A number of other research analysts also recently commented on COYA. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, June 5th. Rodman & Renshaw initiated coverage on shares of Coya Therapeutics in a report on Thursday, June 13th. They set a “buy” rating and a $18.00 price target on the stock.

Coya Therapeutics Price Performance

NASDAQ:COYA opened at $6.11 on Thursday. The stock’s 50-day moving average is $6.28 and its two-hundred day moving average is $7.54. The stock has a market cap of $89.32 million, a PE ratio of -7.19 and a beta of 0.58. Coya Therapeutics has a fifty-two week low of $3.21 and a fifty-two week high of $10.69.

Institutional Investors Weigh In On Coya Therapeutics

Several large investors have recently made changes to their positions in the company. Gilbert & Cook Inc. acquired a new stake in Coya Therapeutics in the second quarter valued at approximately $61,000. Renaissance Technologies LLC acquired a new stake in shares of Coya Therapeutics in the 2nd quarter valued at $101,000. AIGH Capital Management LLC boosted its holdings in Coya Therapeutics by 92.6% in the fourth quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock worth $7,381,000 after purchasing an additional 496,183 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Coya Therapeutics by 772.3% in the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after purchasing an additional 750,338 shares in the last quarter. Finally, Greenlight Capital Inc. increased its position in Coya Therapeutics by 172.2% during the fourth quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock worth $9,441,000 after buying an additional 805,959 shares during the last quarter. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.